Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 1.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,996 shares of the biopharmaceutical company’s stock after selling 4,283 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.23% of Alnylam Pharmaceuticals worth $43,489,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Quent Capital LLC boosted its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $38,000. GAMMA Investing LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $52,000. Finally, V Square Quantitative Management LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $251.03 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $252.87. The firm has a market capitalization of $31.75 billion, a PE ratio of -93.67 and a beta of 0.37. The business’s 50-day simple moving average is $170.20 and its 200-day simple moving average is $166.86.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same period in the prior year, the firm earned ($1.40) earnings per share. The business’s quarterly revenue was up 54.8% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent research reports. Citigroup lifted their price target on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an “equal weight” rating in a research report on Tuesday, June 25th. Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $283.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, June 21st. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.95.

Check Out Our Latest Stock Report on ALNY

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 2,103 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $485,771.97. Following the sale, the chief marketing officer now owns 15,609 shares in the company, valued at $3,605,522.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the sale, the director now owns 8,436 shares in the company, valued at $1,253,589.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,357 shares of company stock valued at $13,436,711. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Featured Stories

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.